BIG 02/98 Docetaxel - Breast Cancer

NCT00174655 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2887

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Doxorubicine + docetaxel sequential
DRUG: doxorubicine + cyclophosphamide sequential
DRUG: doxorubicine + cyclophosphamide combined
DRUG: doxorubicine + docetaxel combined

Sponsor

Sanofi